Epidermal growth factor receptor (EGFR), when overactive or overexpressed, may lead to tumor growth and spread, and is thus a robust target for therapy.
Formosa Pharmaceuticals Inc. and Almac Discovery Ltd. have announced a global licensing agreement for development and commercialization of ALM-401, a first-in-class engineered bispecific antibody-drug conjugate (ADC) for the treatment of solid tumors characterized by the dual expression of EGFR and ROR1.
ALX Oncology Holdings Inc. has received FDA clearance for the IND application for ALX-2004, the company’s potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors.
Black Diamond Therapeutics Inc. is getting $70 million up front and could earn up to $710 million in milestone payments in a deal with Servier for phase I-stage BDTX-4933, a small-molecule candidate targeting both RAS mutations and RAF alternations for treating solid tumors, including non-small-cell lung cancer.
Glioblastomas (GBMs) are the most malignant brain tumors and remain uncurable. Even after therapy, some glioblastoma stem cells (GSCs) survive in the brain parenchyma and cause tumor recurrence.
The U.S. FDA approved Janssen Biotech Inc.’s Rybrevant (amivantamab-vmjw) plus a new oral tyrosine kinase inhibitor called Lazcluze (lazertinib) as a first-line combination treatment to treat select non-small-cell lung cancers.
China’s National Medical Products Administration authorized the country’s first cetuximab biosimilar with the approval of Simcere Zaiming’s Enlituo (CMAB-009, cetuximab beta injection) in combination with chemotherapy as first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer. The biosimilar references originator drug Erbitux (cetuximab, Eli Lilly and Co.).
China’s National Medical Products Administration (NMPA) approved Dizal Pharmaceutical Co. Ltd.’s golidocitinib for treating adults with relapsed or refractory peripheral T-cell lymphoma whose disease has progressed or was refractory to at least one prior systemic therapy.
China’s National Medical Products Administration (NMPA) approved Dizal Pharmaceutical Co. Ltd.’s golidocitinib for treating adults with relapsed or refractory peripheral T-cell lymphoma whose disease has progressed or was refractory to at least one prior systemic therapy.
Intriguing data in pancreatic cancer didn’t do much to help shares of South San Francisco-based Cytomx Therapeutics Inc. (NASDAQ:CTMX), which closed May 9 at $2.04, down $2.15, or 51%, as the company made known initial findings from the ongoing CX-904 phase Ia dose-escalation study, showing a favorable safety profile and confirmed anticancer activity.
